Bone News and Research

RSS

Study compares common treatment options for infants born with clubfoot

Clubfoot affects one in a thousand babies born in the United States, but with proper corrective treatment and follow-up, infants born with clubfoot can have feet compatible with an active, normal lifestyle. A new study in the February 2010 issue of the Journal of Bone and Joint Surgery (JBJS) compared two common treatment options for clubfoot - Ponseti method and surgical treatment.

2 Feb 2010

EPO to grant patent notice to BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”.

2 Feb 2010

GMC designated as NMDP collection site to collect bone marrow from willing donors

Geisinger Medical Center (GMC) was recently designated a National Marrow Donation Program (NMDP) collection site, becoming the only site in the region to collect bone marrow or blood stem cells from willing donors.

2 Feb 2010

New technology aims to restore lost bone and gum tissue following periodontal disease

Advances in tissue engineering are offering the promise of being able to restore lost bone and gum tissue following periodontal disease.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

CHOP deploys medical team for pediatric care in Haiti

Global Health at The Children's Hospital of Philadelphia (CHOP) is deploying a medical team to Haiti today in response to an urgent call from Partners In Health for pediatric experts to care for children with injuries related to the Jan. 12 earthquake at the University Hospital in Port-au-Prince.

31 Jan 2010

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti.

30 Jan 2010

Medical equipment could be a key weapon in stopping nuclear waste seeping into environment

Medical equipment used for diagnosis of patients with heart disease and cancer could be a key weapon in stopping nuclear waste seeping into the environment, according to new research.

From The University of Manchester 30 Jan 2010

$Study shows hip fractures in elderly men are linked to impaired bone health in their grandsons$

Study shows hip fractures in elderly men are linked to impaired bone health in their grandsons

If your grandfather has had a hip fracture, you too could be at risk. Researchers at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have been able to show, for the first time, a link between hip fractures in elderly men and impaired bone health in their grandsons.

30 Jan 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

ASH offers hematologists a new resource for earning CME credits

The American Society of Hematology (ASH) now offers physicians who diagnose and treat blood disorders a new resource for earning continuing medical education (CME) credits while staying abreast of the latest clinical strategies in the rapidly changing field of hematology.

29 Jan 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

DNA Medicine Institute awarded Phase II NASA SBIR grant for developing nanoscale diagnostic technologies

DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced it has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Aeronautics and Space Administration (NASA). The contract is designed to develop nanoscale diagnostic technologies that facilitate whole health analysis in a single drop of blood.

29 Jan 2010

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejection

29 Jan 2010

Arthritis pain relief drug ALEVE now available OTC in British Columbia

This winter, British Columbians may be inspired to increase their activity level and take part in some favourite winter pastimes. For those who have joint and arthritis pain, getting back to doing the activities they love may be more of a challenge. ALEVE(R) is the first over-the-counter naproxen sodium tablet, and is now available province-wide. With just one pill, ALEVE(R) offers convenient access to pain relief for up to 12 hours.

29 Jan 2010

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

29 Jan 2010

Nontoxic drug halts and reverses rheumatoid arthritis

A researcher from Northwestern University Feinberg School of Medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that floats undetected into overactive immune cells responsible for the disease.

29 Jan 2010

Tornier and LifeCell commence enrollment in Conexa Reconstructive Tissue Matrix clinical trial

Tornier, Inc., a global leader in extremities and sports medicine orthopaedics, and LifeCell™ Corporation, a KCI Company, announced today the first 13 patients have been enrolled in a multi-center clinical trial to document the clinical value of Conexa™ Reconstructive Tissue Matrix for the surgical repair of large rotator cuff tears. Conexa™ is a porcine-derived tissue matrix with both biologic and mechanical properties that are important to support the repair of injured or surgically reconstructed soft tissue. Launched by Tornier for orthopaedic applications in October of 2008, Conexa™ has been used successfully in approximately 1,500 patients.

28 Jan 2010

Bone News and Research

Study compares common treatment options for infants born with clubfoot

EPO to grant patent notice to BioMimetic Therapeutics

GMC designated as NMDP collection site to collect bone marrow from willing donors

New technology aims to restore lost bone and gum tissue following periodontal disease

Researchers design bioactive nanomaterial that promotes cartilage growth

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

CHOP deploys medical team for pediatric care in Haiti

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Medical equipment could be a key weapon in stopping nuclear waste seeping into environment

Study shows hip fractures in elderly men are linked to impaired bone health in their grandsons

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

ASH offers hematologists a new resource for earning CME credits

How to recognize heart attack symptoms in younger women

DNA Medicine Institute awarded Phase II NASA SBIR grant for developing nanoscale diagnostic technologies

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

Arthritis pain relief drug ALEVE now available OTC in British Columbia

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

Nontoxic drug halts and reverses rheumatoid arthritis

Tornier and LifeCell commence enrollment in Conexa Reconstructive Tissue Matrix clinical trial

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News